Diseases of the Esophagus

Papers
(The median citation count of Diseases of the Esophagus is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
626 ENDOSCOPIC VACUUM THERAPY FOR ANASTOMOTIC LEAK IN ESOPHAGECTOMY AND TOTAL GASTRECTOMY: A SYSTEMATIC REVIEW AND META-ANALYSIS32
783 C-REACTIVE PROTEIN VERSUS DRAIN AMYLASE; THEIR RELIABILITY IN RULING OUT ANASTOMOTIC LEAKAGE AFTER MINIMALLY INVASIVE IVOR-LEWIS ESOPHAGECTOMY30
Novel histologic score predicts recurrent intestinal metaplasia after successful endoscopic eradication therapy27
285 RIGHT COMPARED WITH LEFT THORACIC APPROACH ESOPHAGECTOMY FOR PATIENTS WITH MIDDLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA23
Identifying the limitations of cardiopulmonary exercise testing prior to esophagectomy using a pooled analysis of patient-level data21
532 OUTCOME OF QUILICI’S HEPATIC SHOULDER PROCEDURE TO AUGMENT LAPAROSCOPIC HIATOPLASTY IN LARGE OR RECURRENT HIATAL HERNIA21
221 THORACOSCOPIC ESOPHAGECTOMY WITH OR WITHOUT SMALL THORACOTOMY FOR ADVANCED THORACIC ESOPHAGEAL CARCINOMA IN THE LEFT LATERAL DECUBITUS POSITION18
166 CLINICAL IMPACT OF NEW BIOMARKERS IN THE PATIENTS WITH ESOPHAGEAL CARCINOMA18
389 THE BEST PRACTICE OF RECONSTRUCTION METHODS AFTER ESOPHAGECTOMY WITHOUT STOMACH18
Correction to: Real-life introduction of powered circular stapler for esophagogastric anastomosis: cohort and propensity matched score study17
Correction to: Radial incision and cutting for dilation before endoscopic submucosal dissection in patients with esophageal cancer on the distal side of severe benign esophageal strictures17
800 ASSOCIATION OF MULTIPLE RAPID SWALLOW PARAMETERS WITH SYMPTOMS IN PATIENTS WITH INEFFECTIVE AND NORMAL ESOPHAGEAL MOTILITY15
54 CLINICOPATHOLOGICAL FEATURES AND TREATMENT OUTCOMES OF ESOPHAGOGASTRIC JUNCTIONAL CARCINOMA TREATED WITH CURATIVE SURGERY15
676 NECESSITY OF EXTENDED LOWER PARATRACHEAL LYMPH NODE RESECTION DURING ESOPHAGECTOMY FOR CANCER14
201: THE YIELD OF DIAGNOSTIC LAPAROSCOPY WITH PERITONEAL LAVAGE IN GASTRIC ADENOCARCINOMA: A MULTICENTRE RETROSPECTIVE COHORT STUDY12
96: EXPERIENCE IN RECONSTRUCTION OF LARYNGOPHARYNGOESOPHAGECTOMIES IN A THIRD LEVEL CENTER12
105: SURGICAL DISSECTION DOES NOT INCREASE FREE CANCER CELLS (FCC) IN PERITONEAL LAVAGE OF PATIENTS FOLLOWING D2 GASTRECTOMY12
62: WHICH GASTRIC CANCER PATIENTS COULD BENEFIT FROM STAGING LAPAROSCOPY? A GIRCG MULTICENTER COHORT STUDY12
205: ADJUNCTIVE SURVEILLANCE MODALITIES AND ONCOLOGIC OUTCOME: A REPORT FROM THE ENSURE STUDY12
50: IDENTIFICATION AND CLASSIFICATION OF TUMOR CELLS IN BARRETT’S CARCINOMA PATIENTS BY HYPERSPECTRAL IMAGING (HSI)12
130: PATTERN OF LYMPH NODE METASTASES IN GASTRIC CANCER—A SIDE-STUDY OF THE MULTICENTER LOGICA-TRIAL11
100: IMPACT OF INCREASING LYMPH NODE YIELD ON THE NUMBER OF POSITIVE LYMPH NODES, MORBIDITY AND SURVIVAL IN ESOPHAGEAL CANCER SURGERY11
146: THE NEED OF CDH1 GERMLINE MUTATION SCREENING IN PATIENTS WITH GASTRIC CANCER IN THE WEST10
104: PERIOPERATIVE STRATEGIES IN ESOPHAGEAL CANCER RESECTION IN 12 NORDIC UNIVERSITY HOSPITALS10
29: INCIDENCE, DIAGNOSIS AND MANAGEMENT OF MALABSORPTION FOLLOWING OESOPHAGECTOMY: A SYSTEMATIC REVIEW10
206: COULD THE PITTSBURGH SEVERITY SCORE GUIDE THE TREATMENT OF ESOPHAGEAL PERFORATION? EXPERIENCE OF A SINGLE REFERRAL CENTER10
190: ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) AND ROBOTIC SENTINEL NODE NAVIGATION SURGERY FOR EARLY GASTRIC CANCER: FIRST EXPERIENCE AND PRELIMINARY RESULTS10
529. ANALYSES OF CLINICAL FACTORS AFFECTING POSTOPERATIVE SYMPTOMS INCLUDING BODY WEIGHT LOSS, ORAL INTAKE, AND REFLUX AFTER ESOPHAGECTOMY FOR ESOPHAGEAL CANCER9
287 OUTCOMES OF DEFINITIVE CHEMORADIOTHERAPY IN LONG SEGMENT ESOPHAGEAL CANCERS FROM A TERTIARY CANCER CENTRE IN INDIA9
241. A VALIDATED NOMOGRAM PREDICTING LYMPH NODE METASTASIS OF T2N0 ESOPHAGEAL SQUAMOUS CELL CARCINOMA FOR CLINICAL DECISION-MAKING9
205. PREDICTORS OF THE DIFFICULTY OF TRANSCERVICAL SUBCARINAL LYMPH NODE DISSECTION IN ESOPHAGEAL CANCER9
90: HOSPITAL VARIATION IN FAILURE TO CURE IN ESOPHAGEAL CANCER SURGERY: IS THE PROPORTION OF PATIENTS UNDERGOING SURGERY PER HOSPITAL PIVOTAL?9
369. GENOMIC ALTERATIONS AND SURVIVAL AFTER TREATMENT OF EAC BY SURGERY WITHOUT CHEMO- OR RADIOTHERAPY9
440. MULTIDISCIPLINARY TREATMENT CONFERENCE IMPROVES SURVIVAL IN ESOPHAGEAL CANCER9
156 THE EXPRESSION AND ROLE OF ANO9 IN HUMAN ESOPHAGEAL SQUAMOUS CELL CARCINOMA9
Safety and effectiveness of mucosal traction using a snare combined with endoclips to assist the resection of esophageal intraepithelial neoplasia: a propensity score matching analysis9
649. MODIFIED EN BLOC ESOPHAGECTOMY WITH TOTAL LYMPHADENECTOMY IN PATIENTS WITH RESIDUAL TUMOR AFTER NEOADJUVANT CHEMORADIOTHERAPY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA8
508. OUTCOME OF NEOADJUVANT CHEMORADIOTHERAPY PLUS SURGERY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN EAST ASIA VERSUS WESTERN EUROPE8
535. ENDOSCOPIC AND THORACOSCOPIC MANAGEMENT OF OESOPHAGEAL PERFORATION8
403. FRAILTY AS A PREDICTOR OF POSTOPERATIVE COMPLICATIONS IN PATIENTS UNDERGOING ESOPHAGECTOMY8
570. INCIDENCE AND ONCOLOGICAL IMPLICATION OF ADRENAL INCIDENTALOMAS IN ESOPHAGEAL CANCER PATIENTS8
640. ESOPHAGECTOMY FOR ESOPHAGEAL AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA IN RYGB PATIENTS. A LITERATURE REVIEW ON OPERATIVE TECHNIQUES, SAFETY AND ONCOLOGIC OUTCOME8
239. EVALUATION OF SUBCARINAL LYMPH NODE DISSECTION AND METASTASIS IN TRANSMEDIASTINAL RADICAL ESOPHAGECTOMY8
475. IMPACT OF SURGERY START TIME ON SHORT TERM OUTCOMES OF ELECTIVE ESOPHAGECTOMY FOR CANCER8
350. SALVAGE RADIATION THERAPY FOR OLIGO-RECURRENCES AFTER RADICAL TREATMENT OF ESOPHAGEAL CANCER7
249. CLINICAL IMPLICATIONS OF CHYLE LEAKAGE FOLLOWING ESOPHAGECTOMY7
298. COMPLIANCE FOR TRIMODALITY TREATMENT OF LOCALLY ADVANCED ESOPHAGEAL CANCER: EXPERIENCE FROM A CANCER CENTRE IN NORTH-EAST INDIA7
586. CIRCUMFERENTIAL HIATAL DISSECTION DURING MINIMALLY INVASIVE ESOPHAGECTOMY CLINICAL AND ONCOLOGICAL OUTCOMES7
461. SURGICAL TREATMENT OF STAGE IV ESOPHAGEAL CANCER AFTER CCRT IMPROVES SURVIVAL7
186. RECURRENT DISEASE AFTER ESOPHAGEAL CANCER SURGERY; A SUBSTUDY OF THE DUTCH NATIONWIDE IVORY STUDY7
331. EFFECTIVENESS OF A SPECIALIZED AMINO ACID SUPPLEMENT CONTAINING CAHMB, L-ARGININE AND L-GLUTAMINE (ABOUND®) IN ESOPHAGEAL CANCER SURGERY7
614. SIGNIFICANCE OF LAPAROSCOPIC SURGERY IN OPEN THORACOTOMY ESOPHAGECTOMY7
643. PRACTICAL IMAGING REVIEW OF EXPECTED FINDINGS AND POSSIBLE COMPLICATIONS RELATED TO MULTIMODAL TREATMENT OF ESOPHAGEAL CANCER7
412. FEASIBILITY AND SAFETY OF MINIMALLY INVASIVE SURGERY FOR OESOPHAGEAL DUPLICATION CYST IN ADULTS– EXPERIENCE FROM AN OESOPHAGO-GASTRIC SURGERY UNIT7
539. SURGICAL TECHNIQUES AND OUTCOMES OF GASTRIC CONDUIT RECONSTRUCTION FOLLOWING ESOPHAGECTOMY BY HAND-ASSISTED LAPAROSCOPIC SURGERY (HALS) FOR ESOPHAGEAL CANCER6
538. A DECADE OF ESOPHAGEAL AND ESOPHAGO-GASTRIC JUNCTION CANCER EPIDEMIOLOGY IN NATIONAL CANCER INSTITUTE MEXICO6
452. OUTCOME OF ESOPHAGEAL RESECTION IN PATIENTS WITH ESOPHAGEAL CANCER WITH HISTOPATHOLOGICALLY CONFIRMED DISTANT METASTASIS6
607. COMPARISON OF RECURRENCE PATTERNS AND SURVIVAL AFTER NEOADJUVANT CHEMORADIOTHERAPY VS. CHEMOTHERAPY FOR ESOPHAGEAL CANCER, A MULTI-CENTER EUROPEAN COHORT STUDY6
641. ALPORT SYNDROME WITH ESOPHAGEAL LEIOMYOMA TREATED WITH CONSERVATIVE DISTAL ROBOTIC MYOTOMY: AVOIDING ESOPHAGECTOMY?6
423. POSTOPERATIVE SKELETAL MUSCLE MASS IN ESOPHAGEAL CANCER SURGERY PATIENTS AFTER NEOADJUVANT CHEMOTHERAPY6
656. EPIMIOLOGICAL ASPECTS OF PROGRESSION FROM BARRETT'S ESOPHAGUS IN DYSPLASIA AND ESOPHAGEAL ADENOCARCINOMA: LONG FOLLOW UP IN A HIGH VOLUME CENTER6
594. TOTALLY MINIMALLY INVASIVE 2-STAGE ESOPHAGECTOMY VERSUS HYBRID 2-STAGE ESOPHAGECTOMY. A SINGLE CENTER EXPERIENCE6
305. SURVIVAL DIFFERENCES ACCORDING TO THE PATHOLOGIC STATUS AFTER NEOADJUVANT THERAPY FOLLOWED BY SURGERY IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA6
266. EXTENSION OF FDG-PET-BASED RADIOMIC MODELS ON IDENTIFICATION OF PATIENTS WITH RESIDUAL ESOPHAGEAL CANCER AFTER NEOADJUVANT CHEMORADIOTHERAPY6
561. VIDEO ASSISTED THORACOSCOPIC ESOPHAGECTOMY WITH ABERRANT VASCULAR ANATOMY6
608. INCIDENCE AND IMPACT OF PREOPERATIVE HIATAL HERNIA IN PATIENTS WITH ESOPHAGEAL CARCINOMA UNDERGOING CURATIVE SURGICAL RESECTION6
562. PROGNOSTIC IMPACT OF CLINICOPATHOLOGICAL FEATURES FOLLOWING METASTECTOMY FOR METACHRONOUS PULMONARY METASTASIS FROM ESOPHAGEAL CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS6
265. SIGNIFICANCE OF AGR2 IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA5
209. THE EFFECT OF ENHANCED RECOVERY AFTER MINIMALLY INVASIVE ESOPHAGECTOMY: A RANDOMIZED CONTROLLED TRIAL5
573. DOES CHEST PAIN AFFECT THE LONG TERM OTCOME OF SURGERY FOR ESOPHAGEAL ACHALASIA?5
340. PROGNOSIS OF DIFFUSELY INFILTRATIVE ESOPHAGEAL SQUAMOUS CELL CARCINOMA5
441. ESOPHAGEAL CANCER MANAGEMENT IN A SWISS REFERRAL CENTER; A 20-YEAR EXPERIENCE5
568. THE PROGNOSTIC EFFECT OF PATHOLOGICAL LYMPH NODE REGRESSION AFTER NEOADJUVANT CHEMOTHERAPY FOR OESOPHAGEAL ADENOCARCINOMA – A MULTICENTRE STUDY5
261. MALNUTRITION DEFINED BY GLIM CRITERIA ASSOCIATES WITH INCREASED RISK OF ADVERSE OUTCOME AFTER OESOPHAGO-GASTRIC CANCER SURGERY5
589. HOW COULD PATIENTS SUPPORT SURGEONS? ANALYSIS OF PATIENT'S SKILLS BEFORE AND AFTER OESOPHAGOGASTRIC SURGERY AND IMPACT ON QUALITY OF LIFE5
308. RIGHT TOP PULMONARY VEIN IS A VENOUS ANOMALY OF WHICH SURGEONS SHOULD BE AWARE IN SUBCARINAL DISSECTION FOR RADICAL ESOPHAGECTOMY5
527. A RIGHT CERVICOTOMIC APPROACH TO RETRIEVE A DENTAL PROSTHESIS FROM THE ESOPHAGUS5
642. RESULTS COMPARING SAFE (SUPERCHARGED CERVICAL ANASTOMOSIS FOR ESOPHAGECTOMY AND GASTRIC PULL-UP) AND NON-SAFE PROCEDURE: PROPENSED MATCHED SCORE STUDY5
178. NEOADJUVANT CHEMORADIOTHERAPY VERSUS CHEMOTHERAPY FOR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; WHICH IS THE OPTIMAL TREATMENT OPTION?5
200. SAFETY AND EFFICACY OF CONVERSION SURGERY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA4
500. DEVELOPMENT AND VALIDATION OF INTRAOPERATIVE RADIATION FIBROSIS SCORE (IRFS) IN PATIENTS UNDERGOING TRANSTHORACIC ESOPHAGECTOMY POST NEOADJUVANT CHEMORADIATION FOR ESOPHAGEAL CANCER4
245. CLINICAL UTILITY OF CTDNA IN LONGITUDINAL MONITORING OF TREATMENT RESPONSES AND RELAPSE IN METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA4
483. UTILITY OF ENDOLUMINAL FUNCTIONAL LUMEN IMAGING IN DIAGNOSIS OF ESOPHAGEAL DYSFUNCTION FOLLOWING BARIATRIC SURGERY4
135. A COMPARISON OF THE INOUE ASSESSMENT METHODS AND THE HILL GRADING OF THE GASTROESOPHAGEAL JUNCTION IN DIAGNOSING REFLUX SYMPTOM SEVERITY, ESOPHAGITIS, AND GERD AMONG PATIENTS WHO UNDERWENT UPPER 4
509. FULLY ROBOTIC IVOR-LEWIS ESOPHAGEAL RESECTION (RAMIE) – TECHNICAL DETAILS OF THE RAMIE PROCEDURE IN THE ROBOT2 TRIAL4
411. MAJOR INTRAOPERATIVE COMPLICATIONS IN MINIMALLY INVASIVE ESOPHAGECTOMIES4
201. PREDICTION OF LYMPH NODE METASTASIS IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA USING GENETIC SIGNATURES FROM LARGE-SCALE GENOMIC REPERTOIRES4
376. THE IMPACT OF OVERALL SURVIVAL ON TWO-FIELD OR THREE-FIELD LYMPHADENECTOMY IN MIDDLE AND LOWER THORACIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA4
155. CAN ANAEROBIC THRESHOLD (AT) PREDICT LENGTH OF STAY IN PATIENTS UNDERGOING IVOR LEWIS OESOPHAGECTOMY4
217. LAPAROSCOPIC FUNDOPLICATION EFFECTIVE IN TREATING REFLUX MICRO-ASPIRATION4
526. SALVAGE SURGERY FOR ESOPHAGEAL CANCER: IS IT TIME TO REFINE SURVEILLANCE CRITERIA?4
295. BILATERAL VOCAL CORD PARALYSIS AFTER HYPOPHARYNGEAL CERVICAL ESOPHAGEAL ESD—AN UNRECOGNISED RARE COMPLICATION4
653. DOES MIE REDUCE PULMONARY COMPLICATIONS IN A REAL-WORLD SCENARIO?4
523. RISK FACTORS ASSOCIATED WITH NOT RECEIVING ADJUVANT CHEMOTHERAPY FOR LOCALLY ADVANCED ESOPHAGOGASTRIC ADENOCARCINOMA4
657. COMPARISON BETWEEN GASTRIC TUBE AND COLOPLASTY IN ESOPHAGECTOMY AND ESOPHAGEAL BYPASS IN ESOPHAGEAL STENOSIS DUE TO INGESTION CORROSIVE SUBSTANCE4
436. DIFFERENCES IN MULTIDISCIPLINARY TEAM ASSESSMENT ON ESOPHAGEAL CANCER PATIENTS IN SWEDEN—A MULTICENTRE STUDY4
651. LAPAROSCOPIC TOTAL FUNDOPLICATION IS SUPERIOR TO MEDICAL TREATMENT FOR REDUCING THE CANCER RISK IN BARRETT'S ESOPHAGUS: A LONG-TERM ANALYSIS4
622. EVALUATION OF THE PSOAS MUSCLE INDEX ON CLINICAL OUTCOMES IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA RECEIVING NEOADJUVANT CHEMOTHERAPY4
743 SIEWERT TYPE II GASTRIC CARDIA CANCER: ANALYSIS OF THE RESULTS OF DIFFERENT SURGICAL OPTIONS3
791 RECURRENT HIATAL HERNIA A HIGH PREDICTOR OF PATHOLOGIC REFLUX AND NEED FOR REINTERVENTION3
Esophageal microbiota composition and outcome of esophageal cancer treatment: a systematic review3
309 ASSOCIATION BETWEEN CERVICAL ANASTOMOSIS METHODS AND ANASTOMOSIS STRICTURE AFTER ESOPHAGECTOMY FOR CANCER3
227. DETERMINING SEVERITY OF ESOPHAGEAL ANASTOMOTIC LEAK IN PATIENTS AFTER ESOPHAGECTOMY: DEVELOPMENT OF THE SEAL SCORE3
476 ICG FLUORESCENCE IN IDENTIFICATION OF THORACIC DUCT3
151 A RANDOMIZED,OPEN CLINICAL TRIAL TO COMPARE THE EFFICACY AND SAFETY OF ANLOTINIB PLUS IRINOTECAN VERSUS IRINOTECAN IN PATIENTS WITH ESCC3
Long-term outcomes after non-curative endoscopic resection for esophageal squamous cell carcinoma followed by additional chemoradiotherapy3
634 ROBOTIC-ASSISTED HIATAL HERNIA AND GASTROESOPHAGEAL DISEASE SURGERY: INITIAL RESULTS AND EXPERIENCE IN A SINGLE INSTITUTION3
721 DOES AGE AFFECT OESOPHAGECTOMY SURVIVAL: A COHORT STUDY3
618 STUDY ON THE RELATIONSHIP BETWEEN GASTROESOPHAGEAL REFLUX SYMPTOMS AND ESOPHAGEAL MICROBIOTA3
745 YIELD OF EXTENDED AND TOTAL MEDIASTINAL LYMPHADENECTOMY IN OESOPHAGEAL CANCER3
563 VARIATION IN TREATMENT PATTERNS AND OUTCOMES FOR RESECTED ESOPHAGEAL CANCER AT DESIGNATED THORACIC SURGERY CENTERS3
Corrigendum to: The influence of the SARS-CoV-2 pandemic on esophagogastric cancer services: an international survey of esophagogastric surgeons3
81 ANTI-REFLUX SURGERY: TOUPET AND DOR TECHNIQUES3
Author Index3
551 INCREASED POSTOPERATIVE MORBIDITY AFTER TOTALLY MINIMALLY INVASIVE ESOPHAGECTOMY FOR CANCER IN ELDERLY PATIENTS3
755 LAPAROSCOPIC REPAIR OF GIANT PARAESOPHAGEAL HERNIAS: A SINGLE CENTER EXPERIENCE AND LITERATURE REVIEW3
680 ACUTE GASTRIC DILATATION: A LIFE-THREATENING EARLY COMPLICATION FOLLOWING LAPAROSCOPIC HIATUS HERNIA REPAIR3
834 ENDOSCOPIC VACUUM THERAPY IN THE MANAGEMENT OF OESOPHAGEAL PERFORATIONS AND POST-OPERATIVE LEAKS3
687 ADVERSE EVENTS DURING MINIMALLY INVASIVE ESOPHAGECTOMY IN PRONE POSITION3
165 CLINICAL IMPACT OF PREOPERATIVE SERUM P53 ANTIBODY TITERS IN 1,487 PATIENTS WITH ESOPHAGEAL CARCINOMA: A MULTI-INSTITUTIONAL STUDY3
806 CERVICAL ESOPHAGEAL PERFORATION: MULTIMODAL APPROACH TO A RARE AND MORBID CONDITION3
341. SEX-RELATED DIFFERENCES IN TREATMENT STRATEGY AND OUTCOMES AFTER ESOPHAGECTOMY FOR CANCER3
369 POOR CORRELATION BETWEEN FDG-PET AND PATHOLOGIC RESULTS AFTER EXPERIMENTAL NEOADJUVANT IMMUNOCHEMOTHERAPY FOR GASTROESOPHAGEAL ADENOCARCINOMA: RESULTS OF A CLINICAL TRIAL3
616 MULTIMODAL TREATMENT OF LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A NETWORK META-ANALYSIS3
Gastro-esophageal diagnostic workup before bariatric surgery or endoscopic treatment for obesity: position statement of the International Society of Diseases of the Esophagus3
697 ESOPHAGECTOMY ANASTOMOTIC LEAKS DECREASE LONG TERM SURVIVAL AFTER SURGERY FOR ESOPHAGEAL CANCER: MOVING FROM RESCUE TO PREVENTION.3
666 EARLY EXTUBATION AFTER ESOPHAGECTOMY IS SAFE. A SYSTEMATIC REVIEW AND META-ANALYSIS3
654 PHARYNGEAL POUCH SURGERY IN OCTO- AND NONAGENARIANS IS SAFE AND EFFECTIVE: A MULTICENTER COMPARATIVE COHORT STUDY3
635. FLEXIBLE ENDOSCOPIC SEPTUM DIVISION FOR ZENKER’S DIVERTICULUM: A SINGLE CENTRE EXPERIENCE2
532. OPERATIVE TRENDS AND CLINICAL OUTCOMES OF OPEN, LAPAROSCOPIC AND ROBOTIC APPROACHES TO HIATAL AND PARAOESOPHAGEAL HERNIAS-A STUDY OF 1834 PATIENTS2
277. FLUORESCENCE-GUIDED ANASTOMOSIS DURING SINGLE-PORT VATS IVOR LEWIS ESOPHAGECTOMY2
233. UTILITY OF SINGLE TRANSHIATAL CHEST DRAINAGE AFTER MINIMALLY INVASIVE OESOPHAGECTOMY: A PROPENSITY-SCORE MATCHED STUDY OF FEASIBILITY2
294. LEARNING CURVE OF MINIMALLY INVASIVE ESOPHAGECTOMY: OUR SERIES, SYSTEMATIC REVIEW OF THE LITERATURE AND META-ANALYSIS2
231. DESCRIBING THE LANDSCAPE OF ESOPHAGECTOMY BETWEEN EASTERN AND WESTERN ESOPHAGEAL SOCIETIES: COMPARATIVE STUDIES FROM THE JAPANESE NCD AND DUTCH DUCA2
606. THE CHANGES OF THORACOSCOPIC OR LAPAROSCOPIC APPROACH FOR SPONTANEOUS ESOPHAGEAL RUPTURE IN JAPAN2
312. THE VALUE OF DETECTING THE GASTRIC TUBE PRESSURE AFTER MINIMALLY INVASIVE ESOPHAGECTOMY: A PROSPECTIVE, UNCONTROLLED EXPLORATORY STUDY2
633. DOES SARCOPENIA PREDICT NEOADJUVANT CHEMOTHERAPY TOXICITY IN OESOPHAGEAL ADENOCARCINOMA PATIENTS?2
387. VALIDATION OF PROMARKERESO, A DIAGNOSTIC BLOOD TEST TO IDENTIFY ESOPHAGEAL ADENOCARCINOMA2
Response to emergency computed tomography evaluation of caustic ingestion2
492. OUTCOMES OF ESOPHAGECTOMY IN THE ELDERLY- IS IT WORTH THE EFFORT?2
647 THE LEFT AND RIGHT RECURRENT LARYNGEAL NERVE LYMPH NODES POSSESS DIFFERENT ANATOMICAL CHARACTERISTICS AND RISK STRATIFICATIONS OF METASTASIS2
547 THE ROLE OF HEAT SHOCK PROTEIN 90 IN HYPOXIA INDUCED ANGIOGENESIS AND EPITHELIAL-MESENCHYMAL TRANSITION OF ESOPHAGEAL SQUAMOUS CELL CANCER2
435. PREVALENCE OF OESOPHAGEAL PREMALIGNANT LESIONS AMONG PATIENTS REFERRED FOR GASTRO-OESOPHAGEAL-DUODENOSCOPY AT A TERTIARY CARE HOSPITAL IN NORTHERN, SRI LANKA2
390. CONTINUED IMPLICATIONS OF THE COVID-19 PANDEMIC ENVIRONMENT ON ESOPHAGEAL CANCER CHARACTERISTICS AND TREATMENT IN THE UNITED STATES2
562. COMPARATIVE ANALYSIS OF THE OUTCOMES OF GASTRECTOMY VS. ENDOSCOPIC SUBMUCOSAL DISSECTION FOR THE TREATMENT OF GASTRIC TUBE CANCER AFTER ESOPHAGECTOMY2
322. IMPACT OF POSTOPERATIVE NUTRITIONAL SUPPORT MODES ON CLINICAL AND PATIENT-REPORTED OUTCOMES IN ENHANCED RECOVERY AFTER ESOPHAGECTOMY FOR CANCER2
404. REAL-WORLD TREATMENT PATTERN OF EOSINOPHILIC ESOPHAGITIS IN JAPAN2
314. TRANSORAL ANTEGRADE T-TUBE INSERTION FOR MANAGEMENT OF OESOPHAGEAL LEAKS FOLLOWING MINIMAL INVASIVE OESOPHAGECTOMY2
492 TUMOR ASSOCIATED MACROPHAGE PROMOTES EPITHELIAL-TO-MESENCHYMAL TRANSITION IN ESOPHAGEAL SQUAMOUS CELL CANCER2
358. IMPLICATIONS ON OVERALL SURVIVAL FROM POSITIVE CIRCUMFERENTIAL RESECTION MARGINS IN OESOPHAGEAL CANCER PATIENTS AT A TERTIARY REFERRAL CENTRE IN ENGLAND2
369. IMPACT OF THE COVID-19 PANDEMIC ON ESOPHAGEAL CANCER PATIENTS UNDERGOING ESOPHAGECTOMY: AN ACS-NSQIP DATABASE ANALYSIS2
471. MANAGEMENT OF EARLY ESOPHAGEAL CANCER - A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS2
347. THE EFFICACY OF CONVERSION SURGERY IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA WITH INVASION OF OTHER ORGANS2
210 SALVAGE SURGERY AFTER DEFINITIVE CHEMORADIOTHERAPY FOR CT4 THORACIC ESOPHAGEAL CANCER2
226. PHILOSOPHICAL CONSIDERATIONS IN SURGICAL INNOVATION2
Is magnetic sphincter augmentation indicated in patients with laryngopharyngeal reflux?2
747 IS 99MTC BONE SCINTIGRAPHY NECESSARY IN THE PREOPERATIVE WORKUP FOR PATIENTS WITH POTENTIALLY RESECTABLE ESOPHAGEAL SQUAMOUS CELL CANCER?2
854 OPTIMIZATION OF SURGICAL DELAY AFTER INDUCTION CHEMORADIATION FOR ESOPHAGEAL CANCER: 10 YEARS RETROSPECTIVE MULTI-CENTER STUDY2
403. ROBOTIC-ASSISTED IVOR LEWIS ESOPHAGECTOMY COMPARED TO CONVENTIONAL MINIMALLY INVASIVE ESOPHAGECTOMY: RESULTS FROM SEVEN HIGH VOLUME ITALIAN CENTERS2
74 LAPAROSCOPIC MANAGEMENT OF A PULSION EPIPHRENIC OESOPHAGEAL DIVERTICULUM SECONDARY TO ACHALASIA.2
612. THE UTILITY OF H ANASTOMOSIS IN INFLATABLE MEDIASTINOSCOPE-ASSISTED TRANSHIATAL ESOPHAGECTOMY FOR ESOPHAGEAL CANCER2
266. NSQIP 5-FACTOR MODIFIED FRAILTY INDEX PREDICTS MORBIDITY BUT NOT MORTALITY AFTER ESOPHAGECTOMY2
300. ENDOSCOPIC FOLLOW-UP OF RADICALLY RESECTED SUBMUCOSAL ESOPHAGEAL ADENOCARCINOMA: PRELIMINARY RESULTS OF AN ONGOING PROSPECTIVE, INTERNATIONAL, MULTICENTER COHORT REGISTRY (PREFER TRIAL)2
Trends and predictors of 30-day readmissions in subjects with eosinophilic esophagitis: results from a national cohort2
245. ESOPHAGECTOMY AFTER NEOADJUVANT CHEMOTHERAPY WITH AN INDICATION FOR CONVERSION SURGERY FOR HIGHLY ADVANCED ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA2
351. CONVERSION SURGERY FOR PATIENTS WITH ESOPHAGEAL CANCER AFTER ICI TREATMENT2
205. MINIMALLY INVASIVE IVOR LEWIS ESOPHAGECTOMY WITH TOTAL MEDIASTINAL LYMPHADENECTOMY FOR THORACIC ESOPHAGEAL CANCER: SHORT- AND LONG-TERM OUTCOMES IN 139 PATIENTS2
332. OUTCOMES OF SALVAGE SURGERY FOR ESOPHAGEAL CARCINOMA: A NATIONWIDE COHORT STUDY2
237. THE PROGNOSTIC VALUE OF NODAL SKIP METASTASIS IN PATIENTS WITH ESOPHAGEAL CANCER2
363. REFLUX MICRO-ASPIRATION: WHAT HAVE WE LEARNED2
335. IMPACT OF POSTOPERATIVE COMPLICATIONS ON LONG-TERM OUTCOMES AFTER ESOPHAGECTOMY2
625. PHASE II TRIAL OF INDUCTION CHEMOTHERAPY FOLLOWED BY CHEMORADIATION AND MINIMALLY INVASIVE SURGERY FOR LOCALLY ADVANCED CARCINOMA OF THE ESOPHAGUS2
224 A RETROSPECTIVE CASE–CONTROL STUDY ASSESSING THE CLINICAL AND ENDOSCOPIC CHARACTERISTICS OF EOSINOPHILIC ESOPHAGITIS IN JAPAN2
Lymphatic invasion is a prognostic factor of pathological N0 esophageal squamous cell carcinoma2
111 CLINICAL IMPORTANCE OF MEAN CORPUSCULAR VOLUME AS A PROGNOSTIC MARKER AFTER ESOPHAGECTOMY FOR ESOPHAGEAL CANCER2
608. ASSOCIATION BETWEEN SYSTEMIC IMMUNE-INFLAMMATION INDEX (SII) AND THE RISK OF ALL-CAUSE, CANCER, AND NON-CANCER MORTALITY IN THE GENERAL POPULATION2
723 TWO- VS. THREE-FIELD LYMPHADENECTOMY FOR ESOPHAGEAL CANCER. A SYSTEMATIC REVIEW AND META-ANALYSIS OF SHORT- AND LONG-TERM OUTCOMES.2
765. PATTERNS, TIMING, AND SURVIVAL OF RECURRENCE FOLLOWING SURGERY FOR ESOPHAGEAL ADENOCARCINOMA IN THE EUROPEAN MULTICENTRE ENSURE STUDY2
Quantitative perfusion assessment of gastric conduit with indocyanine green dye to predict anastomotic leak after esophagectomy1
Diagnostic thresholds and optimal collection protocol of salivary pepsin for gastroesophageal reflux disease1
535. AUDITING THE PATIENTS OUTCOMES AFTER SURGERY FOR ESOPHAGEAL AND GASTRIC CARDIA CANCER WITHIN THE 18 YEARS PERIOD. SINGLE CENTER EXPERIENCE1
214: THE ADDITION OF ENDOSCOPIC ULTRASOUND AND PET IMAGING HAVE MINIMAL IMPACT ON DECISION-MAKING IN EARLY OESOPHAGEAL CANCER1
Current state of rumination syndrome1
538. COMPARISON OF EARLY POSTOPERATIVE OUTCOMES OF CERVICAL ANASTOMOSIS TO HIGH INTRATHORACIC ANASTOMOSIS AMONG PATIENTS WITH UPPER THORACIC ESOPHAGEAL CANCER1
451. ISOFORM SWITCHING EVENTS MAY PROVIDE NEW INSIGHT FOR THE IDENTIFICATION OF PROGNOSTIC AND THERAPEUTIC TARGETS IN ESOPHAGEAL ADENOCARCINOMA1
396. SHORT-TERM REVIEW: REAL-WORD EXPERIENCE OF PEMBROLIZUMAB AS FIRST-LINE CHEMOTHERAPY FOR ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA1
394. USEFULNESS OF INTRAOPERATIVE RECURRENT LARYNGEAL NERVE MONITORING IN REDUCING RECURRENT LARYNGEAL NERVE PARALYSIS AFTER ROBOT-ASSISTED THORACOSCOPIC ESOPHAGECTOMY1
427. THE ROLE OF CROSS-SECTIONAL IMAGING IN PATIENTS WITH PULMONARY MICRO ASPIRATION1
384. ROBUST CULTURE OF PATIENT-DERIVED ESOPHAGEAL ADENOCARCINOMA ORGANOIDS OF SINGLE CELL LINEAGE1
Surgical treatment of esophago-tracheobronchial fistulas after esophagectomy1
411. SINGLE-PORT THORACOSCOPIC RESECTION FOR THE SPINDLE CELL TUMOR OF ESOPHAGUS1
452. THE TREATMENT STRATEGY FOR RECURRENT OR UNRESECTABLE ESOPHAGEAL CANCER USING IMMUNE CHECKPOINT INHIBITORS1
39. HIGH PREOPERATIVE PLATELET TO LYMPHOCYTE RATIO IS ASSOCIATED WITH A GREATER RISK OF POSTOPERATIVE COMPLICATIONS AND RECURRENCES IN ESOPHAGEAL CANCER1
567. EPIDEMIOLOGY OF BARRETT'S ESOPHAGUS IN ICELAND; INCIDENCE AND PROGRESSION TO NEOPLASM FROM A LARGE POPULATION-BASED STUDY1
460. INTRAEPITHELIAL EOSINOPHILS IN ACHALASIA PATIENTS ARE NOT UNCOMMON, BUT THEY SEEM NOT RELATED TO THE COURSE OF THE DISEASE1
270. SAFETY AND EFFICACY OF PREOPERATIVE FOLFOX FOR PATIENTS WITH RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHO ARE NOT CANDIDATES FOR CISPLATIN1
Pressure dynamics of the esophagogastric junction at rest and during inspiratory maneuvers after Nissen fundoplication1
Peroral endoscopic myotomy compared to laparoscopic Heller myotomy and pneumatic dilation in the treatment of achalasia: a systematic review1
470. INTENSIVE EARLY SURVEILLANCE FOLLOWING ESOPHAGECTOMY IDENTIFIES DISTINCT PATTERNS OF RECURRENCE1
Identifying the role of preoperative oral/dental health care in post-esophagectomy pulmonary complications: a systematic review and meta-analysis1
Management and outcomes of esophageal perforation1
Transgastric drainage of the perforated esophagus: our experiences over 10 years1
A senior surgical resident can safely perform complex esophageal cancer surgery after surgical mentoring program—experience of a European high-volume center1
Variability in endoscopic assessment of Nissen fundoplication wrap integrity and hiatus herniation1
Gastric preconditioning via percutaneous angioembolization before esophagectomy in patients at high risk for esophageal leak1
813. SELF-DILATATION FOR THE MANAGEMENT OF REFRACTORY BENIGN OESOPHAGEAL STRICTURES: OUTCOMES FROM THE LARGEST EUROPEAN TERTIARY CENTRE EXPERIENCE TO DATE1
Risk of lymph node metastasis in T1 esophageal adenocarcinoma: a meta-analysis1
571. A PHASE I/II MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF INDUCTION IMMUNOCHEMOTHERAPY FOLLOWED BY CONCURRENT IMMUNO-CHEMORADIOTHERAPY IN UNRESECTABLE LA-ESCC1
Medical management of painful achalasia: a patient-driven systematic review1
204. CORRELATION OF CIRCULATING T LYMPHOCYTES WITH RESPONSE TO NEOADJUVANT CHEMOIMMUNOTHERAPY IN OPERABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA1
739. SIGNIFICANCE OF COX2 INHIBITOR FOR ESOPHAGEAL CANCER FROM THE CLINICAL AND EXPERIMENTAL ESTIMATE1
147. CHARACTERISTICS AND PREDICTORS OF EARLY POSTOPERATIVE RECURRENCE OF ESOPHAGEAL CANCER1
793. MODIFIED HELLER DOR FOR ACHALASIA1
158. PACLITAXEL PLUS CISPLATIN AND 5 FUOROURACIL INDUCTION CHEMOTHERAPY FOR BORDERLINE RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA: 3-YEAR SURVIVAL RESULT1
Can FLIP guide therapy in idiopathic esophagogastric junction outflow obstruction?1
382. CARDIAC REMODELING IN PATIENTS WITH ESOPHAGEAL CANCER-ASSOCIATED CACHEXIA1
796. P02.05 NEOADJUVANT CHEMORADIOTHERAPY FOLLOWED BY ACTIVE SURVEILLANCE VERSUS STANDARD SURGERY FOR OESOPHAGEAL CANCER (SANO-TRIAL): A MULTICENTRE STEPPED-WEDGE CLUSTER-RANDOMISED NONINFERIORITY TRI1
490. SIGNIFICANCE OF NUTRITIONAL EVALUATION USING GLIM CRITERIA IN PATIENTS WITH ESOPHAGEAL CANCER1
444. QUALITY OF LIFE OF CHILDREN AFTER ESOPHAGEAL REPLACEMENT1
327. ANALYSING THE ROLE OF PET-CT IN ESOPHAGEAL CANCER: A SINGLE CENTRE COHORT STUDY1
384. NEOADJUVANT ANLOTINIB COMBINED WITH PENPULIMAB FOR RESECTABLE LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC): A PROSPECTIVE, SINGLE-ARM, PHASE II TRIAL1
347. DEFINITIVE CHEMORADIOTHERAPY WITH DOCETAXEL, CISPLATIN, AND 5-FLUOROURACIL (DCF-RT) FOR ADVANCED CERVICAL ESOPHAGEAL CANCER1
176. NON-REGIONAL LYMPHADENOPATHY IN PATIENTS WITH ESOPHAGEAL CANCER TREATED WITH CURATIVE INTENT: A PROPENSITY MATCHED ANALYSIS OF PATHOLOGICAL AND SURVIVAL OUTCOMES1
803. 2-YEAR RESULTS IN ESOPHAGOGASTRIC JUNCTION CANCER TREATMENT1
Magnetic sphincter augmentation may limit access to magnetic resonance imaging1
The surgical anatomy of a (robot-assisted) minimally invasive transcervical esophagectomy1
100 TOTAL LYMPHOCYTES COUNT (TLC) PREDICTS THE OVERALL SURVIVAL AFTER CHEMORADIOTHERAPY IN ESOPHAGEAL CARCINOMA PATIENTS1
Contemporary outcomes of left thoraco-abdominal esophagectomy due to cancer in the esophagus or gastroesophageal junction, a multicenter cohort study1
771. EVOLUTION OF THE SURGICAL MANAGEMENT OF OESOPHAGEAL PERFORATION1
Research protocol for the Paraesophageal hernia symptom tool, a prospective multi-center cohort study to identify the need and threshold for surgery and assess the symptom response to surgery1
748. CAUSES, TREATMENT AND OUTCOMES OF CONDUIT NECROSIS FOLLOWING OESOPHAGECTOMY: A SINGLE CENTRE RETROSPECTIVE STUDY1
Association of eosinophilic esophagitis with autoimmune and connective tissue disorders, and the impact on treatment response1
613. LAPAROSCOPIC MANAGEMENT OF TYPE IV HIATAL HERNIA WITH MESH AUGMENTATION CRUROPLASTY - EXPERIENCE AT A TERTIARY CARE CENTRE1
805. BOCHDALEK HERNIA - CASE REPORT1
483. INTRAOPERATIVE EVALUATION OF HIATAL HERNIA SIZE AND CANDIDACY IN TIF ELIGIBLE PATIENTS1
392. MACHINE LEARNING TO PREDICT LYMPH NODE METASTASIS IN T1 ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A MULTICENTER STUDY1
487. CAMRELIZUMAB COMBINED WITH CHEMOTHERAPY OR APATINIB AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE 2 TRIAL1
Endoscopic versus fluoroscopic esophageal dilatations in children with esophageal strictures: 10-year experience1
337. PREDICTION OF PULMONARY METASTASIS IN ESOPHAGEAL CARCINOMA PATIENTS WITH INDETERMINATE1
Comparative outcomes of Toupet fundoplication and magnetic sphincter augmentation1
408. COMPARISON OF THE SHORT-TERM EFFICACY OF THORACOSCOPY COMBINED WITH GASTROSCOPY AND TRADITIONAL THORACOTOMY IN THE TREATMENT OF SPONTANEOUS ESOPHAGEAL RUPTURE1
Identifying a core symptom set triggering radiological and endoscopic investigations for suspected recurrent esophago-gastric cancer: a modified Delphi consensus process1
331. IMPACT OF SARCOPENIA ON RECURRENCE OF ESOPHAGOGASTRIC ADENOCARCINOMA IN PATIENTS THAT HAVE UNDERGONE NEOADJUVANT CHEMOTHERAPY1
496. THE OUTCOMES OF NIVOLUMAB FOR ESOPHAGEAL CANCER RECURRENT PATIENTS AFTER NAC-DCF THERAPY1
Assessing the outcomes of posterior thoracic para-aortic lymph node dissection after induction chemotherapy in patients with esophageal squamous cell carcinoma1
269. PATIENT-DERIVED TUMOR ORGANOIDS AND XENOGRAFTS AS BASIC AND PRECLINICAL TRANSLATIONAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MODELS1
542. POST-ESOPHAGECTOMY PARACONDUIT HIATAL HERNIA DEVELOPMENT AND RECURRENCE1
Histologic response to steroids in eosinophilic esophagitis is dependent on delivery compound1
570. ADRENAL METASTASES OF ESOPHAGEAL CANCER: SURGICAL MANAGEMENT OF SINGLE METASTASES1
Is it necessary to routinely perform feeding jejunostomy at the time of esophagectomy? A systematic review and meta-analysis1
0.1188440322876